Bioequivalence study of two tablet formulations of sildenafil

Arzneimittel-Forschung/Drug Research

Volumn 58, Issue 3, 2008, Pages 122-125

  Spínola, Ana Cristina Franco ^a   Almeida, Susana ^a,b   Filipe, Augusto ^a   Tanguay, Mario ^c   Yritia, Mercedes ^d  

^a Tecnimede Group   (Portugal)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Anapharm Canada   (Canada)

^d Anapharm Europe SL   (Spain)

Author keywords

CAS 139755 83 2; Phosphodiesterase type 5, inhibitors; Sildenafil, bioequivalence, pharmacokinetics

Indexed keywords

SILDENAFIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT;

EID: 41849149370     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296480     Document Type: Article

References (8)

1. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phossphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol. 2005;45:987-1003.
2. Mandal U., Musmade P, Chakraborty M, Rajan S, Pal MCTK, Chataraj TK. Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. Boll Chim Farm. 2004 November 9:345-49.
3. European Medicines Agency. European public assessment report (EPAR) Viagra. [Online]. 2005 [cited 2007 Nov 26]; Available from: http://www.emea. europa.eu/humandocs/PDFs/EPAR/viagra/113698en6.pdf.
4. Salonia A, Rigatti P, Montorsi F. Sildenafil in erectile dysfunction: a critical review. Curr Med Res Opin. 2003;19(4):241-262.
5. Mehrotra N, Gupta M, Kovar A, Meibohm B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res. 2007;19:253-264.
6. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98. July 2001.
7. ICH Harmonised Tripartite Guideline. Guideline for good clinical practice E6 (R1). 1996.
8. Guidance for Industry. Bioanalytical Method Validation. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). May 2001.